


methionine hydroxy analogs, and methionine compounds having the structural formula I



and pharmaceutically acceptable N- (mono- and di-carboxylic acid) acyl derivatives of methionine and alkyl esters of methionine compounds and analogs, where n is an integer from 1 to 3.

2. A method according to claim 1 where the methionine compound is in the dl-form.

3. A method according to claim 1 where the methionine compound is in the d-form.

4. A method according to claim 1 where the methionine compound is administered in a daily dosage in the range from 1.0 to 10 grams per 70 kg. of body weight until the inflammation is relieved.

5. A method according to claim 1 where the dosage form contains in addition at least one homocysteine affecting vitamin selected from the group consisting of vitamin B12, B6, or folic acid, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to methionine and cysteine, where the total daily dosage range of vitamin B12, B6 or folic acid corresponds to: vitamin B12, 0.3 to 30 micrograms; vitamin B6, 0.2 to 20 milligrams; folic acid, 40 to 4000 micrograms; and combinations thereof.

6. A method according to claim 1 where the dosage form contains in addition one homocysteine affecting amino acid selected from the group consisting of serine and glycine, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to cysteine, said amount ranging from 1/5 to 3 times the methionine compound.

7. A method according to claim 1 where the dosage form contains in addition at least one dietary antioxidant in an effective amount selected from a group of dietary antioxidants including vitamins A, C, E, selenium and zinc, where the total daily dosage range for each is: vitamin A, 500 to 50,000 IU; vitamin C, 1 to 1000 mg; vitamin E, 1 to 150 IU; selenium, 1 to 200 mcg; zinc, 1 to 150 mg; and combinations thereof.

8. A method according to claim 1 where the dosage form contains in addition a coagulation inhibitor in an anticoagulant effective amount, such inhibitor selected from the group including aspirin, diprydamole, lovastatin, clofibrate, and Dextran 40.

9. A method according to claim 1 for inhibiting inflammatory response in dogs, cows, pigs or cats where the methionine compound is administered as an N-acyl compound in a daily dosage in the range of 5 to 100

milligrams per kg. of body weight until the inflammation is relieved.

10. A method for inhibiting cholesterolemic disease response in a subject in need of such treatment, comprising provision to the subject a foodstuff comprising essentially the food ingredient and a nutritionally adequate amount of a methionine compound as determined by human nitrogen balance studies or other methods validated thereby, selected from the group consisting of the methionine hydroxy analogs, and l- and dl-methionine compounds; and pharmaceutically acceptable N- (mono- and di-carboxylic acid) acyl derivatives of methionine and alkyl esters of methionine compounds and analogs.

11. A method according to claim 10, suitable for administration to persons in an institutional setting where the methionine compound is sufficient to provide total l-methionine content in the final food product of more than 3 grams l-methionine per 100 grams protein but less 15 grams of l-methionine compound per 100 grams protein.

12. A method according to claim 10 where the methionine compound is in the dl-form.

13. A method according to claim 10 where the methionine compound is in the l-form.

14. A method according to claim 10 where the dosage form contains in addition at least one homocysteine affecting vitamin selected from the group consisting of vitamin B12, B6, or folic acid, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to methionine and cysteine, where the total daily dosage range of vitamin B12, B6 or folic acid corresponds to: vitamin B12, 0.3 to 30 micrograms; vitamin B6, 0.2 to 20 milligrams; folic acid, 40 to 4000 micrograms; and combinations thereof.

15. A method according to claim 10 where the dosage form contains in addition one homocysteine affecting amino acid selected from the group consisting of serine and glycine, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to cysteine, said amount ranging from 1/5 to 3 times the methionine compound.

16. A method according to claim 10 where the dosage form contains in addition at least one dietary antioxidant in a synergistically antioxidant effective amount selected from a group of dietary antioxidants including vitamins A,C,E, selenium, and zinc, where the total daily dosage range for each is: vitamin A, 500 to 50,000 IU; vitamin C, 1 to 1000 mg; vitamin E, 1 to 150 IU; selenium, 1 to 200 mcg; zinc, 1 to 150 mg; and combinations thereof.

* * * * *

55

60

65